[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370531-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370531-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","discovery-of-novel-potent-and-orally-bioavailable-smarca2-proteolysis-targeting-chimeras-with-synergistic-antitumor-activity-in-combination-with-kirsten-rat-sarcoma-viral-oncogene-homologue-g12c-inhibitors","Discovery of Novel, Potent, and Orally Bioavailable SMARCA2 Proteolysis-Targeting Chimeras with Synergistic Antitumor Activity in Combination with Kirsten Rat Sarcoma Viral Oncogene Homologue G12C Inhibitors","","Cancer genomic studies report frequent mutations in SWI/SNF chromatin remodeling complex subunits, including SMARCA4, making the complex a common oncogenic alteration. SMARCA2 is identified as synthetic lethal with SMARCA4, supporting SMARCA2 as a high-value therapeutic target. The work discloses cereblon-based SMARCA2 PROTACs that are potent, selective, and orally bioavailable. YDR1 and YD54 degrade SMARCA2, inhibit tumor growth in SMARCA4 mutant models, and synergize with KRAS G12C inhibition to suppress comutant cells.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/discovery-of-novel-potent-and-orally-bioavailable-smarca2-proteolysis-targeting-chimeras-with-synergistic-antitumor-activity-in-combination-with-kirsten-rat-sarcoma-viral-oncogene-homologue-g12c-inhibitors/370531/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/discovery-of-novel-potent-and-orally-bioavailable-smarca2-proteolysis-targeting-chimeras-with-synergistic-antitumor-activity-in-combination-with-kirsten-rat-sarcoma-viral-oncogene-homologue-g12c-inhibitors/370531.png","ImageObject",300,407,{"name":42,"@type":43},"WPS_1786070896","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is SMARCA2 considered a therapeutic target in SMARCA4-mutant cancers?","Question",{"text":63,"@type":64},"SMARCA2 shows synthetic lethal genetic interaction with SMARCA4, including in lung cancer models, indicating vulnerability that can be therapeutically exploited.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What compounds were developed and how do they work?",{"text":68,"@type":64},"The article discloses cereblon-based SMARCA2 PROTACs, including YDR1 and YD54, designed to induce SMARCA2 ubiquitination and proteasomal degradation.",{"name":70,"@type":61,"acceptedAnswer":71},"How does combination therapy with a KRAS G12C inhibitor affect results?",{"text":72,"@type":64},"YDR1 and YD54 synergize with the KRAS G12C inhibitor sotorasib to inhibit growth of lung cancer cells that are comutant for SMARCA4 and KRAS G12C.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370531,1790463668,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},549768072016,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","This article is licensed under CC-BY-NC-ND 4.0  \n[pubs.acs.org/jmc](pubs.acs.org/jmc)  Article   \nDiscovery of Novel, Potent, and Orally Bioavailable SMARCA2 Proteolysis-Targeting Chimeras with Synergistic Antitumor Activity in Combination with Kirsten Rat Sarcoma Viral Oncogene Homologue G12C Inhibitors  \nSasikumar Kotagiri, Yawen Wang, Yanyan Han, Xiaobing Liang, Nicholas Blazanin, Hira Mazhar, Manu Sebastian, Phuong Kieu Nguyen, Yongying Jiang, and Yonathan Lissanu*  \n Cite This: J. Med. Chem. 2025, 68, 9202−9219  \nRead Online  \n\n|  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- |\n| ACCESS   | Metrics & More |  |  Article Recommendations |  | *sı Supporting Information |\n\nABSTRACT: Cancer genomic studies have identified frequent mutations in subunits of the SWI/SNF chromatin remodeling complex, including SMARCA4 in nonsmall cell lung cancer with a frequency of up to 33% in advanced-stage disease, making it the most frequently mutated complex. We and others have identified SMARCA2 to be synthetic lethal to SMARCA4, indicating that SMARCA2 is a high-value therapeutic target. Here, we disclose the discovery and characterization of potent, selective, and orally bioavailable cereblon-based SMARCA2 PROTACs. Biochemically, we showed that YDR1 and YD54 are potent SMARCA2 degraders. Further, we showed the antitumor growth inhibitory activity of YDR1 and YD54 in SMARCA4 mutant xenografts. Finally, we show that YDR1 and YD54 synergize with the KRAS G12C  \ninhibitor sotorasib to inhibit the growth of SMARCA4 and KRAS G12C comutant lung cancer cells. These findings provide evidence for the utility of single agent or combination regimens containing SMARCA2 PROTACs as synthetic lethal therapeutics against SMARCA4 mutant cancers.  \n■ INTRODUCTION  \nA major discovery of large-scale cancer genomic studies is the identification of frequent mutations in subunits of the SWI/ SNF (switch/sucrose non-fermenting) chromatin remodeling complex, including SMARCA4 (also known as BRG1) and ARID1A, ranging from 16% in early-stage disease to 33% in advanced lung cancer. 1−7 Additionally, a meta-analysis of 44 cancer genomic studies has shown that 20% of all solid tumors have mutations in subunits of the SWI/SNF complex, making it one of the most frequently mutated complexes in cancer.6 The SWI/SNF complex is a large multisubunit complex that uses ATP hydrolysis to remodel nucleosomes and enable chromatin-dependent processes such as transcription, DNA repair, and replication.8,9 SMARCA2 (also known as BRM) and SMARCA4 are mutually exclusive core catalytic subunits with ATPase enzymatic activity. Mutations in SMARCA4 are inactivating and cannot be directly targeted therapeutically. Thus, there is an intense effort to identify synthetic lethal or other vulnerabilities in SMARCA4 mutants. While several studies have reported enhanced sensitivity of SMARCA4 mutant lung cancers to inhibition of oxidative phosphorylation (OXPHOS), 10 Aurora kinase A,11 EZH2, 12 ATR, 13 and KDM6 methyltransferases,14 none of these have progressed into  \n© 2025 The Authors. Published by American Chemical Society  \nclinical success. Importantly, we and others have identified that the paralog SMARCA2 shows a synthetic lethal genetic interaction with SMARCA4 in lung cancer cell lines, suggesting that it is a high-value therapeutic target. 15−20 SMARCA2 is composed of helicase-SANT-associated (HSA) domain, DEXDc, and Helicase domains (that together constitute the ATPase domain), Snf2 ATP coupling (SnAC) domain, and bromodomain. From these, the ATPase and bromodomains are readily amenable to small molecule inhibition. As anticancer agents, inhibitors targeting the bromodomain were found to be not efficacious, while those targeting the ATPase domain of SMARCA2 were not selective and associated with undesired off-target activities against other ATPases such as SMARCA4, highlighting the need for alternative approaches of targeting SMARCA2 . 16,21 Proteolysis-targeting chimeras (PROT","cbCaihql0hYCfLos","https://ap.wps.com/l/cbCaihql0hYCfLos","pdf",11213155,18,"English","# Abstract\n# Introduction","[{\"question\":\"Why is SMARCA2 considered a therapeutic target in SMARCA4-mutant cancers?\",\"answer\":\"SMARCA2 shows synthetic lethal genetic interaction with SMARCA4, including in lung cancer models, indicating vulnerability that can be therapeutically exploited.\"},{\"question\":\"What compounds were developed and how do they work?\",\"answer\":\"The article discloses cereblon-based SMARCA2 PROTACs, including YDR1 and YD54, designed to induce SMARCA2 ubiquitination and proteasomal degradation.\"},{\"question\":\"How does combination therapy with a KRAS G12C inhibitor affect results?\",\"answer\":\"YDR1 and YD54 synergize with the KRAS G12C inhibitor sotorasib to inhibit growth of lung cancer cells that are comutant for SMARCA4 and KRAS G12C.\"}]","Discovery of Novel, Potent, and Orally Bioavailable SMARCA2 Proteolysis-Targeting Chimeras with Synergistic Antitumor Activity in Combination with Kirsten Rat Sarcoma Viral Oncogene Homologue G12C Inhibitors | PDF",1790189018,45,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/98817cda0dd53fb1ecd6fbda52af8b7f.webp",983,1296,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/570da32676742a7adcd1c56d6e5cda80.webp",982,1295,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d9c2b3a7bfcdaeb1fbf7bb1acad21787.webp",981,1293,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/488092f64227cf2e464217c812635fe7.webp",980,1292]